These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 24976077)

  • 1. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
    Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
    Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of miRNAs in urine of prostate cancer patients.
    Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
    Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
    Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
    Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of urine-circulating miRNAs for detection of prostate cancer.
    Stuopelyte K; Daniunaite K; Bakavicius A; Lazutka JR; Jankevicius F; Jarmalaite S
    Br J Cancer; 2016 Sep; 115(6):707-15. PubMed ID: 27490805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A panel of five circulating microRNAs as potential biomarkers for prostate cancer.
    Chen ZH; Zhang GL; Li HR; Luo JD; Li ZX; Chen GM; Yang J
    Prostate; 2012 Sep; 72(13):1443-52. PubMed ID: 22298030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing.
    Song C; Chen H; Wang T; Zhang W; Ru G; Lang J
    Prostate; 2015 Apr; 75(5):500-16. PubMed ID: 25597612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.
    Yang B; Liu Z; Ning H; Zhang K; Pan D; Ding K; Huang W; Kang XL; Wang Y; Chen X
    Cancer Biomark; 2016 Jul; 17(2):223-30. PubMed ID: 27434290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
    Jin W; Fei X; Wang X; Chen F; Song Y
    J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases.
    Dülgeroğlu Y; Eroğlu O
    Microrna; 2020; 9(4):303-309. PubMed ID: 33155933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
    Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
    Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candidate diagnostic miRNAs that can detect cancer in prostate biopsy.
    Paziewska A; Mikula M; Dabrowska M; Kulecka M; Goryca K; Antoniewicz A; Dobruch J; Borowka A; Rutkowski P; Ostrowski J
    Prostate; 2018 Feb; 78(3):178-185. PubMed ID: 29226351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
    Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
    Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in Cancer Biomarker Discovery Exemplified by the Identification of Diagnostic MicroRNAs in Prostate Tissues.
    Ambrozkiewicz F; Karczmarski J; Kulecka M; Paziewska A; Cybulska M; Szymanski M; Dobruch J; Antoniewicz A; Mikula M; Ostrowski J
    Biomed Res Int; 2020; 2020():9086829. PubMed ID: 32462034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis.
    Barceló M; Castells M; Bassas L; Vigués F; Larriba S
    Sci Rep; 2019 Sep; 9(1):13772. PubMed ID: 31551516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular RNAs from Whole Urine to Distinguish Prostate Cancer from Benign Prostatic Hyperplasia.
    Stella M; Russo GI; Leonardi R; Carcò D; Gattuso G; Falzone L; Ferrara C; Caponnetto A; Battaglia R; Libra M; Barbagallo D; Di Pietro C; Pernagallo S; Barbagallo C; Ragusa M
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer.
    Byun YJ; Piao XM; Jeong P; Kang HW; Seo SP; Moon SK; Lee JY; Choi YH; Lee HY; Kim WT; Lee SC; Cha EJ; Yun SJ; Kim WJ
    Investig Clin Urol; 2021 May; 62(3):340-348. PubMed ID: 33834642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.